Skip to content
drillr.ai
Sign up

JAZZ

Jazz Pharmaceuticals Plc

NASDAQ · Healthcare · Biotechnology · IE

$208.43
−0.86%
Ask drillr

  • Oct 19, 2026, 20:15 UTC

    Jazz Pharmaceuticals announced that it will report its 2026 third-quarter financial results on November 2, 2026, after the close of U.S. markets, and host a webcast at 4:30 p.m.

    Source:

  • Oct 9, 2026, 13:11 UTC

    Jazz Pharmaceuticals plc reported that Executive Vice President and Chief Commercial Officer Samantha Pearce is retiring.

  • Sep 23, 2026, 20:17 UTC

    Jazz Pharmaceuticals plc amended its credit agreement to reprice and extend its Tranche B-2 Dollar Term Loans, converting $1.895 billion of outstanding principal into new Tranche B-3 Dollar Term Loans maturing May 5, 2033, with the interest rate cut by 50 basis points to Term SOFR + 1.75%.

  • Sep 15, 2026, 13:00 UTC

    Jazz Pharmaceuticals completed its acquisition of privately-held Actio Biosciences for $820 million upfront, adding the clinical-stage epilepsy therapy ABS-1230 to its pipeline.

    Source:

  • Aug 31, 2026, 10:00 UTC

    Jazz Pharmaceuticals announced second interim overall survival results from the Phase 3 HERIZON-GEA-01 trial showing Ziihera plus chemotherapy significantly improved overall survival versus trastuzumab plus chemotherapy in first-line HER2+ advanced gastroesophageal adenocarcinoma.

    Source:

  • Aug 27, 2026, 04:30 UTC

    Jazz Pharmaceuticals announced concurrent ordinary share repurchases in connection with the pricing of its exchangeable senior notes offering.

    Source:

  • Aug 26, 2026, 11:00 UTC

    Jazz Pharmaceuticals announced a private offering of $1.0 billion aggregate principal amount of exchangeable senior notes due 2032, with an option for initial purchasers to buy up to an additional $150 million.

    Source:

  • Aug 26, 2026, 00:02 UTC

    Jazz Pharmaceuticals announced plans for the U.S. launch of Ziihera, a therapy approved by the FDA for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).

    Source:

  • Aug 25, 2026, 14:00 UTC

    The U.S. FDA approved Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) with and without tislelizumab plus chemotherapy for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

    Source:

  • Aug 10, 2026, 11:30 UTC

    Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent consideration, adding the clinical-stage precision therapy ABS-1230 for KCNT1+ epilepsy.

    Source:

  • Aug 3, 2026, 20:05 UTC

    Jazz Pharmaceuticals announced its second quarter 2026 financial results, reporting record total revenues of $1.2 billion, a 16% increase year-over-year.

    Source:

  • Jun 17, 2026, 11:43 UTC

    Jazz Pharmaceuticals and AbCellera entered into a research collaboration and licensing agreement to develop T-cell engaging multispecific antibodies for cancer.

    Source:

  • Jun 12, 2026, 12:53 UTC

    Jazz Pharmaceuticals' lung cancer drug Zepzelca failed to meet the main goal of improving overall survival in a late-stage study.

    Source: